| Sep 13 |
Centessa Pharmaceuticals Announces Pricing of Upsized $225,000,000 Public Offering of American Depositary Shares
|
| Sep 11 |
Centessa Pharmaceuticals announces $150M proposed public offering of American Depositary Shares
|
| Sep 11 |
Centessa Pharmaceuticals Announces $150,000,000 Proposed Public Offering of American Depositary Shares
|
| Sep 10 |
Top Midday Gainers
|
| Sep 10 |
Sleep-Disorder Focused Centessa Pharmaceuticals Unveils Interim Data From Lead Program In Acutely Sleep-Deprived Healthy Volunteers
|
| Sep 10 |
Centessa stock jumps 10% on Phase 1 narcolepsy study for ORX750
|
| Sep 10 |
Centessa Rockets To Three-Year High On $5 Billion Narcolepsy Opportunity
|
| Sep 10 |
Investors are waking up to Centessa’s sleepiness drug
|
| Sep 10 |
Centessa Announces Positive Interim Phase 1 Clinical Data with its Novel Orexin Receptor 2 (OX2R) Agonist, ORX750, in Acutely Sleep-Deprived Healthy Volunteers
|
| Aug 27 |
Centessa Pharmaceuticals Announces Late-Breaking Poster Presentation of Non-Human Primate Data for ORX142, a Novel Orexin Receptor 2 (OX2R) Agonist, at the 27th Congress of the European Sleep Research Society (Sleep Europe 2024)
|
